On the basis of these findings, we propose that inhibiting the DARS1-AS1/YBX1 axis may lead to HRD in GBM and make it vulnerable to PARPi therapy. The gene discussed is DARS1; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.